Key facts
- Immuneel’s last known valuation is $67.9M.
- It has raised $38.0M; the latest was Later Stage VC ($12.0M) in Jul 2024.
- Notable investors include Khosla Ventures, F-Prime Capital, Eight Roads, Ranjan Pai, True North — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Immuneel
- ·The full record, as it builds
Funding rounds
No funding rounds for Immuneel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immuneel
Developer of a cell therapy intended to provide cell and gene therapies for cancer treatment. The company develops CAR-T cell therapies extracted from patients' blood cells by using genetic engineering that modifies healthy immune cells to target cancerous cells, enabling cancer patients to access transformational cell-based immunotherapies.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2018
- Employees
- 78
- Website
- immuneel.com/
- Ownership
- Privately Held (backing)
Immuneel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immuneel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immuneel in its N-PORT filings yet. We sweep new filings monthly.